• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Supply and demand for plasma-derived medicinal products - A critical reassessment amid the COVID-19 pandemic.血浆源性药品的供需——新冠疫情期间的关键重新评估
Transfusion. 2020 Nov;60(11):2748-2752. doi: 10.1111/trf.16078. Epub 2020 Sep 9.
2
Transfusion services operations during the COVID-19 pandemic: Results from AABB survey.新冠疫情期间的输血服务运营：美国血库协会调查结果
Transfusion. 2020 Nov;60(11):2760-2762. doi: 10.1111/trf.15986.
3
Transfusion medicine during COVID-19 outbreak in the hotspot of Spain.西班牙疫情热点地区新冠疫情期间的输血医学
Transfusion. 2020 Nov;60(11):2762-2764. doi: 10.1111/trf.16038. Epub 2020 Sep 28.
4
Rolling with the changes.随变化而变。
Transfusion. 2020 May;60(5):885. doi: 10.1111/trf.15809. Epub 2020 Apr 22.
5
Strategic issues currently facing the US blood system.美国血液系统当前面临的战略问题。
Transfusion. 2020 May;60(5):1093-1096. doi: 10.1111/trf.15769. Epub 2020 Apr 27.
6
Emergency response to COVID-19 epidemic: One Chinese blood centre's experience.应对 COVID-19 疫情的紧急反应：一家中国血液中心的经验。
Transfus Med. 2021 Jun;31(3):155-159. doi: 10.1111/tme.12719. Epub 2020 Sep 30.
7
Challenges associated with blood banks and blood donations during the COVID-19 pandemic.2019冠状病毒病大流行期间血库和献血方面的相关挑战。
Am J Emerg Med. 2021 May;43:281-282. doi: 10.1016/j.ajem.2020.06.058. Epub 2020 Jun 30.
8
SARS-CoV-2/COVID-19 pandemic: first wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative report.SARS-CoV-2/COVID-19 大流行：全面整合的区域血液和组织库中的第一波疫情、影响、应对措施和经验教训。叙述性报告。
Blood Transfus. 2021 Mar;19(2):158-167. doi: 10.2450/2021.0259-20. Epub 2021 Jan 15.
9
Provision of COVID-19 Convalescent Plasma in a Resource-Constrained State.在资源有限的情况下提供 COVID-19 恢复期血浆。
Transfusion. 2020 Dec;60(12):2828-2833. doi: 10.1111/trf.16118. Epub 2020 Oct 8.
10
Effects of the COVID-19 pandemic on supply and use of blood for transfusion.新冠疫情对输血用血供应和使用的影响。
Lancet Haematol. 2020 Oct;7(10):e756-e764. doi: 10.1016/S2352-3026(20)30186-1. Epub 2020 Jul 3.

引用本文的文献

1
Understanding supply sustainability of plasma-derived medicinal products: Drivers and consequences of shortages.了解血浆衍生药品的供应可持续性：短缺的驱动因素及后果
Vox Sang. 2025 Aug;120(8):754-764. doi: 10.1111/vox.70052. Epub 2025 May 26.
2
[Strategic independence: a value model for improving access to plasma-derived medicines in Latin AmericaIndependência estratégica: modelo de valor para melhorar o acesso a hemoderivados na América Latina].[战略独立性：改善拉丁美洲血浆衍生药物可及性的价值模型 战略独立性：改善拉丁美洲血液制品可及性的价值模型]
Rev Panam Salud Publica. 2025 May 12;49:e49. doi: 10.26633/RPSP.2025.49. eCollection 2025.
3
Hyperoncotic human albumin solutions for intravenous fluid therapy: Effectiveness of pathogen safety and purification methods, and clinical safety.用于静脉输液治疗的高渗人白蛋白溶液：病原体安全性和纯化方法的有效性及临床安全性
Biosaf Health. 2022 Dec 17;5(1):21-29. doi: 10.1016/j.bsheal.2022.12.004. eCollection 2023 Feb.
4
Report of the Ninth Asian National Control Laboratory Network meeting in 2024, with a focus on regional harmonization of regulatory systems to prepare for cross-border transfer of plasma.2024年第九次亚洲国家控制实验室网络会议报告，重点是监管系统的区域协调，为血浆跨境转移做准备。
Biologicals. 2025 May;90:101823. doi: 10.1016/j.biologicals.2025.101823. Epub 2025 Feb 23.
5
Intravenous immunoglobulin therapy: usage patterns and response to treatment in Qatar over ten years.静脉注射免疫球蛋白疗法：卡塔尔十年间的使用模式及治疗反应
Front Immunol. 2024 Dec 2;15:1481079. doi: 10.3389/fimmu.2024.1481079. eCollection 2024.
6
Recombinant Alpha-1 Antitrypsin-Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study.重组α-1抗胰蛋白酶-Fc融合蛋白INBRX-101用于α-1抗胰蛋白酶缺乏症成人患者：一项1期研究。
Chronic Obstr Pulm Dis. 2024 May 29;11(3):282-292. doi: 10.15326/jcopdf.2023.0469.
7
Shortage of plasma-derived medicinal products: what is next? narrative literature review on its causes and counteracting policies in Italy.血浆衍生药品短缺：接下来会怎样？意大利关于其原因及应对政策的叙述性文献综述
Front Pharmacol. 2024 May 6;15:1375891. doi: 10.3389/fphar.2024.1375891. eCollection 2024.
8
Quality and safety for substances of human origins: scientific evidence and the new EU regulations.人类源物质的质量与安全：科学证据及欧盟新法规
BMJ Glob Health. 2024 Apr 21;9(4):e015122. doi: 10.1136/bmjgh-2024-015122.
9
Barriers and enablers to and strategies for promoting domestic plasma donation throughout the world: Overarching protocol for three systematic reviews.促进全球国内血浆捐献的障碍、促进因素和策略：三项系统评价的总方案。
PLoS One. 2023 Dec 21;18(12):e0296104. doi: 10.1371/journal.pone.0296104. eCollection 2023.
10
Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.体重和年龄对原发性免疫缺陷病患者皮下或透明质酸酶辅助皮下免疫球蛋白 G 药代动力学的影响。
J Clin Immunol. 2023 Nov;43(8):2127-2135. doi: 10.1007/s10875-023-01572-x. Epub 2023 Sep 29.

本文引用的文献

1
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.恢复期血浆治疗重症 COVID-19：一项倾向评分匹配对照研究。
Nat Med. 2020 Nov;26(11):1708-1713. doi: 10.1038/s41591-020-1088-9. Epub 2020 Sep 15.
2
Early safety indicators of COVID-19 convalescent plasma in 5000 patients.5000 例 COVID-19 恢复期血浆治疗的早期安全性指标。
J Clin Invest. 2020 Sep 1;130(9):4791-4797. doi: 10.1172/JCI140200.
3
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.恢复期血浆疗法对重症和危及生命的 COVID-19 患者临床改善时间的影响：一项随机临床试验。
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.
4
SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children.SARS-CoV-2 诱导的川崎样超炎症综合征：儿童新型 COVID 表型。
Pediatrics. 2020 Aug;146(2). doi: 10.1542/peds.2020-1711. Epub 2020 May 21.
5
Google Trends as an early indicator for shortages of intravenous immunoglobulin (IVIG).谷歌趋势作为静脉注射免疫球蛋白（IVIG）短缺的早期指标。
Transfusion. 2020 Aug;60(8):1656-1657. doi: 10.1111/trf.15835. Epub 2020 May 12.
6
Convalescent plasma for patients with COVID-19.新冠康复者血浆用于新冠肺炎患者。
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12528. doi: 10.1073/pnas.2006961117. Epub 2020 May 12.
7
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19.常规静脉注射免疫球蛋白治疗对新型冠状病毒肺炎（COVID-19）重症肺炎患者预后的影响。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.044. Epub 2020 Apr 10.
8
Deployment of convalescent plasma for the prevention and treatment of COVID-19.恢复期血浆在 COVID-19 预防和治疗中的应用。
J Clin Invest. 2020 Jun 1;130(6):2757-2765. doi: 10.1172/JCI138745.
9
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.恢复期血浆疗法治疗重症 COVID-19 患者的疗效。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
10
Source plasma collection in the United States: Toward a more personalized approach.美国的源血浆采集：迈向更个性化的方法。
Am J Hematol. 2020 Jun;95(6):E139-E142. doi: 10.1002/ajh.25817. Epub 2020 Apr 20.

Supply and demand for plasma-derived medicinal products - A critical reassessment amid the COVID-19 pandemic.

作者信息

Hartmann Jan, Klein Harvey G

机构信息

Department of Medical Affairs and Clinical Development, Haemonetics Corporation, Boston, Massachusetts, USA.

Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.

出版信息

Transfusion. 2020 Nov;60(11):2748-2752. doi: 10.1111/trf.16078. Epub 2020 Sep 9.

DOI:10.1111/trf.16078
PMID:32856742
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7460929/
Abstract
摘要